keyboard_arrow_up

2015 Brazil Pharmaceuticals and Healthcare Industry Research Report

Continued regulatory improvements, growing pharmaceutical and healthcare markets, and increased favour for foreign investment will allow Brazil to maintain its position as the regional outperformer in Latin America. However, low affordability and increasing generic drug competition will hamper opportunities for innovative drugmakers as the country continues to develop its economy. Headline Expenditure Projections Pharmaceuticals: BRL62.0bn (USD26.3bn) in 2014 to BRL65.3bn (USD25.6bn) in 2015; +5.2% in local currency terms and -2.8% in US dollar terms. Forecast in local currency has been maintained from Q115 while US dollar growth sees limited development due to depreciating Brazilian Real.

Purchase a Copy of this Report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=308966 .

Table Of Contents

Industry View 7
SWOT 9
Political 11
Economic 12
Operational Risk 13
Industry Forecast 15
Pharmaceutical Market Forecast . 15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Brazil 2011-2019) 16
Healthcare Market Forecast 17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Brazil 2011-2019) 19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Brazil 2011-2019) 19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Brazil 2011-2019) 19
Prescription Drug Market Forecast 20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Brazil 2011-2019) 21
Patented Drug Market Forecast 22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Brazil 2011-2019) 23
Generic Drug Market Forecast 24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Brazil 2011-2019) 27
OTC Medicine Market Forecast 28
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Brazil 2011-2019) 29
Pharmaceutical Trade Forecast 30
Table: Pharmaceutical Trade Data And Forecasts (Brazil 2013-2019) 32
Table: Pharmaceutical Trade Data And Forecasts local currency (Brazil 2013-2019) 33
Key Risks To BMI's Forecast Scenario 34
Macroeconomic Forecasts 36
Economic Analysis 36
Table: GDP By Expenditure (Brazil 2012-2019) 41
Industry Risk Reward Ratings 42
Americas Risk/Reward Index 42
Brazil Risk/Reward Index 46
Rewards 47
Risks 47
Market Overview 48
Industry Trends And Developments 49
Epidemiology 49
Healthcare Sector 51
Table: Healthcare Resources 52
Table: Healthcare Activity 52
Table: Healthcare Personnel 53
Research & Development 55
Biotechnology 57
Clinical Trials 63
Regulatory Development 65
Intellectual Property Issues 68
Counterfeit Drugs 69
Compulsory Licensing 70
Pricing Regime 71
Reimbursement Regime 73
Protectionist Measures 77
Competitive Landscape 80
Table: Top 10 Pharmaceutical Companies In Brazil By Sales In 2013 80
Innovative Drugmakers 80
Generic Drugmakers 86
OTC Sector 90
Pharmaceutical Distribution Sector 91
Pharmaceutical Retail Sector 92
Company Profile . 96
Aché/Biosintética 96
EMS Sigma 100
Eurofarma 103
Medley 106
Cristália 109
Sanofi 112
Pfizer 115
Merck & Co 119
Novartis 123
GlaxoSmithKline 127
Table: GSK'S Strong Collaborative Efforts In Public-Private Partnerships (Ppps) In Brazil 129
Roche 130
Demographic Forecast 133
Table: Population Headline Indicators (Brazil 1990-2025) 134
Table: Key Population Ratios (Brazil 1990-2025) 134
Table: Urban/Rural Population & Life Expectancy (Brazil 1990-2025) 135
Table: Population By Age Group (Brazil 1990-2025) 135
Table: Population By Age Group % (Brazil 1990-2025) 136
Glossary 138
Methodology 140
Pharmaceutical Expenditure Forecast Model 140
Healthcare Expenditure Forecast Model 140
Notes On Methodology 141
Risk/Reward Index Methodology 142
Index Overview 143
Table: Pharmaceutical Risk/Reward Index Indicators 143
Indicator Weightings 144

View Complete Report @ http://www.rnrmarketresearch.com/brazil-pharmaceuticals-and-healthcare-report-q2-2015-market-report.html .